...Alvogen will acquire generics play DreamPharma for $187 million in cash. Alvogen said the deal, which...
...portfolio of over 100 products. Alvogen develops, manufactures and distributes generic, brand and biosimilar products. DreamPharma Corp....

...NeuroBloc in the EU, Norway, Iceland, Liechtenstein, Monaco, Switzerland, Croatia, Turkey, Russia and Japan, and DreamPharma Corp....

...NeuroBloc in the EU, Norway, Iceland, Liechtenstein, Monaco, Switzerland, Croatia, Turkey, Russia and Japan, while DreamPharma Corp....

...Solstice granted DreamPharma exclusive Korean development rights to Myobloc ( NeuroBloc in Europe) botulinum toxin type...
...the U.S. and Europe to treat cervical dystonia pain. Solstice Neurosciences Inc. , Malvern, Penn. DreamPharma Corp....